Twelve years of cyclosporine in pediatric heart transplantation: what is the future?
Parisi
F
F
Pediatric Hospital Bambino Gesù, Rome, Italy.
Abbattista
A D
AD
Squitieri
C
C
Vinciguerra
G
G
La Vigna
G
G
Di Donato
R
R
Catena
G
G
D000293:Adolescent; D001379:Azathioprine / Q000627:therapeutic use; D009202:Cardiomyopathies / Q000601:surgery; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006330:Heart Defects, Congenital / Q000601:surgery; D016027:Heart Transplantation / Q000276:immunology / Q000401:mortality / Q000502:physiology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007223:Infant; D007231:Infant, Newborn; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation / Q000276:immunology / Q000401:mortality; D008727:Methotrexate / Q000627:therapeutic use; D012086:Reoperation; D012189:Retrospective Studies; D013256:Steroids / Q000627:therapeutic use; D015996:Survival Rate; D013997:Time Factors
D007166:Immunosuppressive Agents; D013256:Steroids; D016572:Cyclosporine; D001379:Azathioprine; D008727:Methotrexate